Clinical Trials Logo

Filter by:
NCT ID: NCT02466191 Completed - Pendular Nystagmus Clinical Trials

Treatment of Pendular Nystagmus in OPT

Start date: June 2015
Phase: Phase 4
Study type: Interventional

Pendular nystagmus corresponds to an enduring to and fro eye oscillation without resetting quick phases. The most common causes of acquired pendular nystagmus (APN) are multiple sclerosis (MS) and focal brainstem lesions (oculopalatal tremor, OPT). Based on pathophysiological hypothesis, pharmacological treatments of acquired nystagmus have been thoroughly proposed over different publications of cases, series, reviews or expert opinions. Acquired pendular nystagmus underwent the most rigorous treatment trials, leading to the proposal of gabapentin or memantine as valuable drugs. Whether gabapentin and memantine are effective in APN associated with OPT remains unclear, since none of the previous studies has evaluated the effect of these medications in a group of OPT patients. However, this is an important issue in prospect to a clinical use of these medications. In the current study, the investigators aim is to evaluate the effect of gabapentin and memantine on the mean velocity, amplitude and frequency of pendular nystagmus, as well as on visual acuity and vision-specific health-related quality of life score, in a group of OPT patients

NCT ID: NCT02465970 Completed - Epilepsy Clinical Trials

Effects of Transcranial Direct Current Stimulation (TDCS) in Drug-resistant Partial Epilepsy

BRAINSTIM
Start date: November 13, 2015
Phase: Phase 2
Study type: Interventional

Drug-resistant partial epilepsy has a heavy impact on quality of life and sometimes on life expectancy itself. Only a minority of patients may benefit from a curative epilepsy surgery. Neurostimulation, which can be an effective add-on treatment, is currently mainly represented by vagus nervus stimulation. Transcranial direct current stimulation, a non -invasive technique already used in other areas of neurology, may be efficient on some partial epilepsies, in particular through the individual configuration of stimulation, made possible by recent technological advances. Main goal : To study the effect of transcranial electrical stimulation on the frequency of seizures in patients with drug-resistant partial epilepsy. Hypothesis : Reduction of 50% or more in the frequency of occurrence of seizures within 24 hours following an individually configured TDCS session: responders in real TDCS vs placebo stimulation.

NCT ID: NCT02465905 Completed - Cow's Milk Allergy Clinical Trials

Oral Immunotherapy in Cow's Milk Allergy (CMA) in Children : "Petit Lait" Study

Petit Lait
Start date: June 2012
Phase: N/A
Study type: Interventional

Prospective study Main objective: to evaluate the efficiency and the security of two protocols of immunotherapy (raw milk versus heated milk) in a cohort of children with persistent Immunoglobulin E (IgE) mediated CMA (IgE-CMA). Secondary objectives: to determinate if the enumeration of casein-specific IL-4- and IL-13-secreting T cells could be a valuable biomarker of successful immunotherapy.

NCT ID: NCT02465567 Completed - COPD Clinical Trials

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

Start date: June 30, 2015
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.

NCT ID: NCT02465515 Completed - Diabetes Mellitus Clinical Trials

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Start date: July 1, 2015
Phase: Phase 4
Study type: Interventional

Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.

NCT ID: NCT02465476 Completed - Skin Disease Clinical Trials

Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine

Telemalrares
Start date: January 6, 2015
Phase: N/A
Study type: Interventional

The investigators want to demonstrate that a new organization with telemedicine could rationalize the treatment pathway of patient suffering from rare skin disease. A diagnosis and a personalised treatment pathway could be performed before the consultation in the hospital.

NCT ID: NCT02465450 Completed - Cystic Fibrosis Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

Start date: September 29, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with cystic fibrosis (CF).

NCT ID: NCT02464982 Completed - Breast Cancer Clinical Trials

Psycho-esthetic Impact of Tattoo Technology as Part of Mammary Reconstruction After Surgery Against Breast Cancer

Start date: February 2012
Phase: N/A
Study type: Observational

Mammary reconstruction replaces total skin transplant, which may causing patient discomfort. It is a simple, painless and reproductible technology that avoids consequences and complications related to transplant. Tattoo helps patients to return faster to the normal life and close more easily the cancer episode. The study purpose is to measure the patient's esthetic satisfaction degree on 1year areola tattoo realized following standard care.

NCT ID: NCT02464969 Completed - Clinical trials for Venous Thromboembolism

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Start date: November 22, 2015
Phase: Phase 4
Study type: Interventional

To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

NCT ID: NCT02464488 Completed - Atrial Fibrillation Clinical Trials

New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study

ADAGE
Start date: January 1, 2015
Phase:
Study type: Observational

Several new oral direct anticoagulants have been recently marketed. However, only a few, limited, studies have provided data about the pharmacology of new oral direct anticoagulants in older persons. This study try to better define wether the pharmacology of each of these 3 drugs (dabigatran, rivaroxaban and apixaban) is actually significantly different in very older patients (over 80) and to which extend. The investigators also try to characterize the main determinants (age, weight, renal function, co-morbidities, etc) of the variability observed between individuals in their response to he drugs studied. The method employed is a population pharmacokinetic/pharmacodynamic study.